تخطى إلى المحتوى / Skip to content
Clinical Reference Hub

Rheumatoid Arthritis

Chronic systemic autoimmune disease primarily affecting synovial joints, causing inflammation, pain, swelling, and potential joint destruction.

Medical disclaimer: This page is an educational clinical-decision-support reference for licensed healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. If you are a patient with symptoms, consult a qualified physician. Always verify dosing and guidance against current clinical guidelines and the cited references.

🩺What is Rheumatoid Arthritis?

The DAS28 was developed by Prevoo et al. in 1995 and validated as a reliable measure of RA disease activity. The 28-joint count includes shoulders, elbows, wrists, MCPs, PIPs, and knees (excluding hips, ankles, and feet). The composite score incorporates four components: tender joint count (TJC28), swollen joint count (SJC28), acute phase reactant (ESR by Westergren method or CRP), and patient global assessment of disease activity on a 100 mm VAS.

ICD-10 Classification Code:M05

🏥Signs & Symptoms

The following clinical signs and symptoms are commonly assessed when evaluating Rheumatoid Arthritis:

  • Symmetrical joint pain, swelling, and stiffness
  • Morning stiffness lasting more than 30 minutes
  • Involvement of small joints of hands and feet
  • Fatigue, low-grade fever, and weight loss
  • Rheumatoid nodules
  • Reduced grip strength and functional limitation

🔬Causes & Etiology

Rheumatoid arthritis is a chronic autoimmune inflammatory disease primarily affecting synovial joints, driven by autoantibodies and inflammatory cytokines.

Genetic susceptibility (HLA-DR4 and other loci) combined with environmental triggers such as smoking and infections initiates the disease.

⚠️Risk Factors

The following factors are known to increase the risk of developing or worsening Rheumatoid Arthritis:

  • Female sex
  • Family history of rheumatoid arthritis
  • Smoking, the strongest environmental factor
  • Obesity
  • Periodontal disease and other infections
  • Age of onset between 40 and 60 years

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Rheumatoid Arthritis:

  • DAS28 — Disease Activity Score 28 for Rheumatoid Arthritis

    The DAS28 (Disease Activity Score 28) is the most widely used composite index for assessing disease activity in rheumatoid arthritis (RA). It combines tender and swollen joint counts (28-joint assessment), acute phase reactant (ESR or CRP), and patient global assessment into a single score for monitoring treatment response and guiding therapy decisions.

  • ACR/EULAR 2010 RA Classification Criteria

    The 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA) were developed to enable earlier diagnosis and classification of RA compared to the 1987 ACR criteria. The criteria assign points across four domains: joint involvement, serology, acute phase reactants, and symptom duration.

  • HAQ-DI — Health Assessment Questionnaire Disability Index

    The Health Assessment Questionnaire Disability Index (HAQ-DI) is a validated patient-reported outcome measure that assesses functional disability across eight domains of daily living: dressing, arising, eating, walking, hygiene, reach, grip, and activities. It is widely used in rheumatoid arthritis and other rheumatic diseases.

🧬Diagnostic Logic & Scoring Breakdown

The DAS28 is calculated using four components. Tender Joint Count (TJC28): count of painful joints on palpation from the 28-joint assessment (0-28). Swollen Joint Count (SJC28): count of swollen joints from the same 28-joint assessment (0-28). Acute Phase Reactant: either ESR (erythrocyte sedimentation rate in mm/h) using the DAS28-ESR formula, or CRP (C-reactive protein in mg/L) using the DAS28-CRP formula. Patient Global Assessment (PGA): patient-reported overall disease activity on a 0-100 mm visual analogue scale. For DAS28-ESR: 0.56√(TJC) + 0.28√(SJC) + 0.70 ln(ESR) + 0.014(PGA). For DAS28-CRP: 0.56√(TJC) + 0.28√(SJC) + 0.36 ln(CRP+1) + 0.014(PGA) + 0.96. The DAS28-CRP formula includes a correction factor (+0.96) to improve concordance with DAS28-ESR. Interpretation: <2.6 remission, 2.6-3.2 low disease activity, >3.2-5.1 moderate disease activity, >5.1 high disease activity.

📢Clinical Significance & Implications

The DAS28 is the most validated and widely used disease activity measure in rheumatoid arthritis clinical practice and trials. It is endorsed by the American College of Rheumatology (ACR), European Alliance of Associations for Rheumatology (EULAR), and treat-to-target recommendations. The DAS28 has been validated against radiographic progression, functional status (HAQ-DI), and patient-reported outcomes. A change of >0.6 is considered clinically meaningful, and >1.2 represents a major response. The treat-to-target strategy recommends targeting DAS28 <2.6 (remission) or at least <3.2 (low disease activity).

🛡️Prevention & Management

Evidence-based prevention and management strategies for Rheumatoid Arthritis include:

  • Early diagnosis and initiation of DMARD therapy to prevent joint damage
  • Smoking cessation
  • Regular low-impact physical activity and physical therapy
  • Weight management
  • Regular cardiovascular and bone health monitoring

Complications & Prognosis

Without proper management, Rheumatoid Arthritis may lead to the following complications:

Progressive erosive joint damage, deformities, and disability.

Extra-articular manifestations: interstitial lung disease, vasculitis, and rheumatoid nodules.

Increased risk of cardiovascular disease and osteoporosis.

💡 Clinical Assessment Scenario Example

A 45-year-old woman with RA: TJC28 = 8, SJC28 = 6, ESR = 35 mm/h, PGA = 60/100. DAS28-ESR = 0.56×√(8) + 0.28×√(6) + 0.70×ln(35) + 0.014×60 = 0.56×2.83 + 0.28×2.45 + 0.70×3.56 + 0.84 = 1.58 + 0.69 + 2.49 + 0.84 = 5.60. High disease activity. Recommendation: Escalate DMARD, consider biologic therapy, urgent rheumatology referral.

💊Common Medications & Interventions

The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Rheumatoid Arthritis:

MethotrexateConventional Synthetic DMARD
HydroxychloroquineConventional Synthetic DMARD
AdalimumabTNF Inhibitor (Biologic DMARD)
PrednisoneCorticosteroid
SulfasalazineDMARD — Sulfa Agent
LeflunomideDMARD — Pyrimidine Synthesis Inhibitor
TocilizumabIL-6 Receptor Inhibitor

⚠️Clinical Assessment Pitfalls

  • Mistake: Including hips, ankles, and feet in the 28-joint count

    Correction: The DAS28 specifically uses a 28-joint count excluding hips, ankles, and feet. If these joints are involved, they should be documented separately but do not contribute to the DAS28 score.

  • Mistake: Using ESR in mm/h and CRP in mg/dL interchangeably without unit conversion

    Correction: DAS28-ESR uses ESR in mm/h (Westergren). DAS28-CRP uses CRP in mg/L. If CRP is reported in mg/dL, multiply by 10 to convert to mg/L before using the formula.

  • Mistake: Applying the criteria to patients without objective synovitis (e.g., arthralgia only)

    Correction: The criteria require at least one clinically swollen joint on examination. Do not apply to patients with joint pain without swelling or to those with non-inflammatory joint diseases.

  • Mistake: Counting all joints including DIPs, first MTP, and first CMC in the joint score

    Correction: DIPs of hands and feet, first MTP joints, and first CMC joints are excluded from the joint count per the criteria definition.

  • Mistake: Scoring serology based on RF alone without anti-CCP or vice versa

    Correction: Both RF and anti-CCP should be tested. Score the highest applicable category from the combined serology: if both are low-positive, score remains 2; if either is high-positive, score becomes 3.

  • Mistake: Using the criteria to exclude RA diagnosis in seronegative patients with typical RA presentation

    Correction: Patients can meet the criteria through joint involvement alone (0-5 points) plus acute phase (1 point) and duration (1 point) for a total of 7/10, even with negative serology. The criteria are for classification, not diagnosis — clinical judgment remains paramount.

  • Mistake: Not adjusting domain scores upward when the patient uses aids or devices

    Correction: According to the standard HAQ scoring, if a patient uses aids, devices, or requires assistance from another person for a domain, the minimum score for that domain should be 2 (with much difficulty), even if the patient reports less difficulty. This adjustment ensures accurate representation of true functional status.

  • Mistake: Using HAQ-DI alone without assessing disease activity (DAS28)

    Correction: HAQ-DI measures functional disability, which is influenced by both disease activity and structural damage. It should be interpreted alongside disease activity measures like DAS28 to differentiate active inflammation from permanent joint damage as a cause of disability.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Rheumatoid Arthritis; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

Frequently Asked Questions

Q: What is the difference between DAS28-ESR and DAS28-CRP?

DAS28-ESR uses the erythrocyte sedimentation rate (Westergren method) while DAS28-CRP uses C-reactive protein. DAS28-CRP includes a correction factor of +0.96 to better align with DAS28-ESR. CRP is less affected by age, sex, and immunoglobulins than ESR, making it more specific for inflammation. However, clinical trials traditionally used DAS28-ESR. Both are acceptable for clinical practice, but the same formula should be used consistently for longitudinal monitoring of individual patients.

Q: How often should DAS28 be measured?

The treat-to-target strategy recommends assessing disease activity with DAS28 every 1-3 months during active disease to guide treatment adjustments. Once the treatment target (remission or low disease activity) is achieved and sustained, monitoring can be extended to every 3-6 months. More frequent assessment may be needed when tapering therapy or during flares.

Q: How do the 2010 ACR/EULAR criteria differ from the 1987 ACR criteria?

The 2010 criteria differ in several key ways: (1) They do not require radiographic erosions or rheumatoid nodules, enabling earlier diagnosis; (2) They use a weighted scoring system rather than a checklist; (3) They include anti-CCP antibodies separately from RF; (4) They incorporate acute phase reactants; (5) They emphasize small joint involvement; (6) They establish a minimum symptom duration of 6 weeks rather than the 1987 requirement for 6 weeks of arthritis. These changes improved sensitivity for early RA from approximately 0.50 (1987) to 0.84 (2010), with maintained specificity of 0.91.

Q: Can patients with seronegative RA be classified using these criteria?

Yes. Joint involvement (up to 5 points) combined with acute phase reactants (1 point) and symptom duration (1 point) can yield a score of 7/10 even with negative serology, meeting the threshold for definite RA. However, careful exclusion of alternative diagnoses is especially important in seronegative patients, as conditions like psoriatic arthritis, reactive arthritis, and SLE may also present with polyarthritis.

Q: Should the criteria be applied in primary care or only in rheumatology settings?

The criteria were developed and validated in rheumatology clinic populations. While they can be used in primary care as a screening tool, they perform with lower specificity in this setting due to the higher prevalence of non-inflammatory joint conditions. Any patient meeting the criteria in primary care should be referred to rheumatology for confirmation and management. The joint count requires clinical expertise to distinguish synovitis from periarticular swelling.

Q: What is the minimal clinically important difference (MCID) for HAQ-DI?

The MCID for HAQ-DI is approximately 0.22-0.25 points on the 0-3 scale. In clinical trials, a change of 0.22-0.25 is considered a small but meaningful improvement. A change of 0.5 is considered moderate improvement, and a change of 1.0 or more is considered major improvement. The HAQ-DI is sensitive to change with effective DMARD therapy.

Q: Can HAQ-DI distinguish between disability from active inflammation vs permanent joint damage?

The HAQ-DI measures overall functional status but does not distinguish between reversible disability from active inflammation and irreversible disability from structural joint damage. To make this distinction, HAQ-DI should be interpreted alongside disease activity measures (DAS28, CRP/ESR) and imaging findings. Improvement in HAQ-DI with treatment suggests reversible inflammatory component, while persistent HAQ-DI elevation despite controlled inflammation suggests structural damage.

📚Evidence-Based References

[1]
Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48.PubMed (7818570)
[2]
Van der Heijde DM, van 't Hof MA, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20(3):579-581.PubMed (8478878)
[3]
Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3-15.PubMed (25969430)
[4]
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.PubMed (20872595)
[5]
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-1588.PubMed (20699241)
[6]
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.PubMed (3358796)
[7]
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038.PubMed (27156434)
[8]
van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum. 2011;63(1):37-42.PubMed (20967854)
[9]
Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137-145.PubMed (7362664)
[10]
Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol. 2003;30(1):167-178.PubMed (12508408)
[11]
Anderson J, Sayles HR, Curtis JR, et al. Converting modified Health Assessment Questionnaire (HAQ) scores: converting between the HAQ-DI and the MDHAQ. J Rheumatol. 2012;39(8):1675-1679.
Call Us
WhatsApp